JP2024547113A - Ｇｌｐ－１受容体作動薬の薬学的に許容される塩、結晶形及びその調製方法 - Google Patents

Ｇｌｐ－１受容体作動薬の薬学的に許容される塩、結晶形及びその調製方法 Download PDF

Info

Publication number
JP2024547113A
JP2024547113A JP2024537986A JP2024537986A JP2024547113A JP 2024547113 A JP2024547113 A JP 2024547113A JP 2024537986 A JP2024537986 A JP 2024537986A JP 2024537986 A JP2024537986 A JP 2024537986A JP 2024547113 A JP2024547113 A JP 2024547113A
Authority
JP
Japan
Prior art keywords
methyl
powder
compound
ray diffraction
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024537986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547113A5 (enExample
Inventor
▲偉▼▲棟▼ ▲陸▼
谷▲軍▼ 徐
俊然 ▲楊▼
▲啓▼云 邵
振▲興▼ 杜
君 ▲馮▼
峰 ▲賀▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2024547113A publication Critical patent/JP2024547113A/ja
Publication of JP2024547113A5 publication Critical patent/JP2024547113A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024537986A 2021-12-23 2022-12-23 Ｇｌｐ－１受容体作動薬の薬学的に許容される塩、結晶形及びその調製方法 Pending JP2024547113A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111584574 2021-12-23
CN202111584574.4 2021-12-23
PCT/CN2022/141418 WO2023116882A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法

Publications (2)

Publication Number Publication Date
JP2024547113A true JP2024547113A (ja) 2024-12-26
JP2024547113A5 JP2024547113A5 (enExample) 2026-01-08

Family

ID=86901360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024537986A Pending JP2024547113A (ja) 2021-12-23 2022-12-23 Ｇｌｐ－１受容体作動薬の薬学的に許容される塩、結晶形及びその調製方法

Country Status (11)

Country Link
US (1) US20250049777A1 (enExample)
EP (2) EP4455141B1 (enExample)
JP (1) JP2024547113A (enExample)
KR (1) KR20240125003A (enExample)
CN (1) CN118434730A (enExample)
AU (1) AU2022418658A1 (enExample)
CA (1) CA3241670A1 (enExample)
DK (1) DK4455141T3 (enExample)
MX (1) MX2024007906A (enExample)
TW (1) TW202328114A (enExample)
WO (1) WO2023116882A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202535353A (zh) * 2024-01-09 2025-09-16 大陸商山東盛迪醫藥有限公司 一種ｇｌｐ－１ｒ激動劑醫藥組成物及其應用
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CU20210042A7 (es) * 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
EP4166142A4 (en) * 2020-06-10 2024-06-26 Medshine Discovery Inc. Methyl-substituted benzobisoxazole compound and use thereof
CN119930605A (zh) * 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022228490A1 (zh) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
WO2023116882A1 (zh) 2023-06-29
MX2024007906A (es) 2024-07-10
DK4455141T3 (da) 2026-04-27
KR20240125003A (ko) 2024-08-19
AU2022418658A1 (en) 2024-07-11
CN118434730A (zh) 2024-08-02
CA3241670A1 (en) 2023-06-29
TW202328114A (zh) 2023-07-16
EP4455141A4 (en) 2025-04-09
EP4455141A1 (en) 2024-10-30
US20250049777A1 (en) 2025-02-13
EP4455141B1 (en) 2026-03-25
EP4732838A2 (en) 2026-04-29

Similar Documents

Publication Publication Date Title
US20250049777A1 (en) Pharmaceutically acceptable salt and crystalline form of glp-1 receptor agonist and preparation method therefor
US20250049778A1 (en) Crystalline form of glp-1 receptor agonist and preparation method therefor
EP4332102A1 (en) Isoquinolone compound and use thereof
TW202220962A (zh) 選擇性NaV抑制劑的結晶形式及其製備方法
KR20250116731A (ko) 갑상선 호르몬 β 수용체 작용제, 그 결정형, 제조 방법 및 용도
US20240374581A1 (en) Salt types of tricyclic tetrahydro isoquinoline derivative
US20250361226A1 (en) Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
TWI914461B (zh) 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
US20250353839A1 (en) Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
WO2024236025A1 (en) New polymorphs of (s)-6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide in crystalline form
TW202434600A (zh) 磺醯胺衍生物結晶形式及其製備方法
CN112500353B (zh) 一种左西孟旦的前药化合物、制备方法及其应用
TW202408504A (zh) 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途
WO2021004487A1 (zh) 噻唑烷二酮衍生物以及包含其的药物组合物
WO2023151660A1 (zh) 一种p2x3受体拮抗剂的结晶形式及其制备方法
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2023151658A1 (zh) 一种p2x3受体拮抗剂的可药用盐及其制备方法
CN120535504A (zh) 一种p38α-MK2抑制剂的晶型及其制备方法和应用
WO2022095930A1 (zh) Atx抑制剂氘代衍生物及其应用
WO2021175225A1 (zh) 三环类化合物及其应用
CN121889383A (zh) 一种cyp11a1抑制剂、其制备方法及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251223